Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Michael MontemurroAngela CioffiJulien DômontPiotr RutkowskiArnaud D RothRoger von MoosRoman InauenMaud ToulmondeRoger O BurkhardClaudio KnuesliSebastian BauerPhilippe CassierHeike SchwarbAxel Le CesneDieter KoeberleDaniela BärtschiDaniel DietrichChristine BiaggiJohn O PriorSerge LeyvrazPublished in: Cancer (2018)
Dasatinib produced high metabolic response rates in TKI-naive patients with FDG-PET/CT-positive GIST. Cancer 2018;124:1449-54. © 2018 American Cancer Society.